A remarkable milestone has been achieved in England's fight against cervical cancer, with official data revealing a groundbreaking statistic: for the first time on record, no women aged 20-24 have died from the disease between 2020 and 2024. This achievement is credited to the success of the Human Papillomavirus (HPV) vaccination programme, which has been shown to be highly effective in preventing infections and cancers.
Professor Peter Sasieni of Queen Mary University of London describes the results as 'stunning', highlighting the profound impact of the vaccine on preventing tragic young deaths. Historically, around 23 deaths would have been anticipated in this age bracket over a five-year period. The absence of cervical cancer fatalities for five consecutive years is a testament to the vaccine's efficacy and the success of public health initiatives in achieving high uptake rates among young women.
The HPV vaccine was first introduced in 2006, with girls aged 12 or 13 being offered it since 2008 as part of the national programme. In 2019, the programme was expanded to include boys, not only protecting them from HPV-related cancers but also reducing the spread of the virus. As an infection that can be sexually transmitted, certain strains of HPV have been linked to a significantly increased risk of cancer development.
While existing data has shown that the HPV vaccine reduces infection rates and cervical cancer incidence, this latest analysis provides definitive evidence that it also prevents deaths from these cancers. Researchers, including Professor Sasieni and Milena Falcaro, had previously questioned whether the vaccine mainly prevented cancers detectable through screening. Thankfully, the data suggests that it prevents cancers that could have been missed by screening, thus preventing fatalities.
The high vaccination rate among young women in England is a key factor in this success, with around 90% of those aged 20-24 having received the HPV vaccine during their early teenage years. Caroline Temmink, director of vaccination for the NHS in England, welcomes the news as evidence of the life-saving impact of the vaccine and highlights the prospect of a generation being free from the risk of cervical cancer and other HPV-related cancers.
However, concerns have been raised about a decline in HPV vaccine uptake since the COVID-19 pandemic. Experts warn that sustained low vaccination rates could lead to an increase in cervical cancer cases and deaths in the UK. The NHS continues to stress that alongside cervical screening, HPV vaccination is crucial to its ambition of eliminating cervical cancer by 2040, urging all eligible individuals to take up the offer when invited.